SureTrader Nadex Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 2/23/2017 1:55:48 PM - Followers: 188 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CVM News: Current Report Filing (8-k) 02/21/2017 05:04:30 PM
CVM News: CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference 02/21/2017 08:45:00 AM
CVM News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 02/17/2017 05:25:29 PM
CVM News: CEL-SCI Announces $1.0 Million Registered Direct Offering 02/17/2017 08:30:00 AM
CVM News: Current Report Filing (8-k) 02/13/2017 03:41:58 PM
PostSubject
#8718  Sticky Note Do with this information what you will,... I drkazmd65 09/26/16 01:49:06 PM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#10451   In @ .0932. Probably add EOD or tomorrow. GMONEY4 02/23/17 01:55:48 PM
#10450   Volume coming in now. GMONEY4 02/23/17 10:37:26 AM
#10449   I assume some have become "events" and the Foxwoods Man 02/23/17 06:57:23 AM
#10448   I guess if you look at it that Foxwoods Man 02/23/17 06:56:28 AM
#10447   Still being monitored. trickledownfacists 02/22/17 06:45:15 PM
#10446   Come on, FM! We still have rheumatoid ducruacuteo11 02/22/17 06:25:01 PM
#10445   Does anybody know what happened to the 926 ducruacuteo11 02/22/17 06:15:19 PM
#10444   Thanks. Maybe our boy will reduce the hampshiremaynard 02/22/17 05:18:35 PM
#10443   Ok..let's use 10 cents as a present share Foxwoods Man 02/22/17 04:48:59 PM
#10442   Any chance you can explain this for me? hampshiremaynard 02/22/17 04:41:02 PM
#10441   Yup....but starting at a crap share price AND Foxwoods Man 02/22/17 04:40:07 PM
#10440   Maybe, maybe not. $50 million arb win trickledownfacists 02/22/17 04:36:43 PM
#10439   Probably...and we will be below five cents by Foxwoods Man 02/22/17 04:34:31 PM
#10438   I think all bets are on positive Arb trickledownfacists 02/22/17 04:30:58 PM
#10437   My opinion (stated previously) is that they went Foxwoods Man 02/22/17 04:28:20 PM
#10436   Is the fat lady on stage yet? ducruacuteo11 02/22/17 04:17:47 PM
#10435   I think they have to let that buyer hampshiremaynard 02/22/17 04:03:10 PM
#10434   Big wall @ .093 GMONEY4 02/22/17 03:56:17 PM
#10433   Let's see if .09 holds. GMONEY4 02/22/17 03:37:46 PM
#10432   EOD is your best bet trickledownfacists 02/22/17 03:30:33 PM
#10431   Me too. I'm also keeping a "buying eye" Daddy Rick 02/22/17 03:29:25 PM
#10430   Endless dumping today. Glad I didn't jump in. GMONEY4 02/22/17 03:19:44 PM
#10429   CVM gonna' net around $800K on stock placement: Daddy Rick 02/22/17 11:20:43 AM
#10428   Not officially closed but agreed upon. trickledownfacists 02/22/17 09:19:06 AM
#10427   Didn't you post on that last night? GMONEY4 02/22/17 09:18:43 AM
#10426   Where did you see the press on that? trickledownfacists 02/22/17 09:16:44 AM
#10425   Party on. Offering closed. .104 x .1049 GMONEY4 02/22/17 09:14:10 AM
#10424   I couldn't agree and disagree more. I am learning curve 02/22/17 12:57:16 AM
#10423   I think you are all over the map. StrategyTrader 02/22/17 12:25:45 AM
#10422   Maybe later this week or early next week learning curve 02/21/17 11:39:34 PM
#10421   Me offended....not in the least. I share learning curve 02/21/17 11:24:39 PM
#10420   Well, I was going on pure technical lightrock 02/21/17 06:59:44 PM
#10419   ...and that would be a GOOD thing Foxwoods Man 02/21/17 05:27:34 PM
#10418   Ok, well... lightrock 02/21/17 05:25:32 PM
#10417   8k Looks like the offering was completed trickledownfacists 02/21/17 05:11:05 PM
#10416   http://www.businessinsider.de/how-fda-drug-approval-works-2017-2?r=US&IR=T Go KingLui 02/21/17 03:08:17 PM
#10415   I couldn't agree more. warfaretrader 02/21/17 12:15:05 PM
#10414   Ya, I'm sure a hell of a lot trickledownfacists 02/21/17 10:53:54 AM
#10413   I do appreciate this effort by the company Foxwoods Man 02/21/17 10:50:51 AM
#10412   Each time we had an R/S our share steve2150 02/21/17 10:06:33 AM
#10411   Red already. I'll leave it in for awhile. GMONEY4 02/21/17 09:59:09 AM
#10410   My theory is they are shopping Cel-4000 around trickledownfacists 02/21/17 09:19:16 AM
#10409   So you pulling the fork out? trickledownfacists 02/21/17 09:08:29 AM
#10408   News out. GMONEY4 02/21/17 08:46:45 AM
#10407   As you like to say, "What are you warfaretrader 02/21/17 08:12:13 AM
#10406   If anybody bites... I will provide the next learning curve 02/21/17 01:33:41 AM
#10405   Look at the current share price, do you sinity 02/20/17 01:45:47 PM
#10404   Yes, all true. trickledownfacists 02/20/17 11:32:18 AM
#10403   Anyone else find it interesting that Geert or hampshiremaynard 02/20/17 10:29:42 AM
#10402   Because I would save it for what is lightrock 02/20/17 01:07:09 AM
PostSubject